We invite you to register for a 1,5 hour webinar called “Clinical Trial Update 2023”. The goal of the webinar is to update the OI-community about ongoing clinical trials – both those who are recruiting and others. This includes the following trials: – The Cosmic and the Orbit trials (setrusumab) – The BoostB4 trial (stem…
Interview with Dr. Winnie Liu, Oregon Health and Science University (OHSU), Portland, Oregon, USA Dr. Winnie Liu is an adult endocrinologist and takes care of patients at Oregon Health and Science University (OHSU) located in Portland, Oregon. Her clinical and research interests are metabolic bone disease with a focus on OI after joining the BBDC (Brittle…
TOPaZ is a randomised open-label clinical trial for people with osteogenesis imperfecta (OI). The study aims to investigate whether a two-year spell of treatment with a drug called teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with OI. The TOPaZ trial receives…
Treatment of OI with Parathyroid hormone and Zoledronic acid Interview with Prof. Stuart H. Ralston, University of Edinburgh, Western General Hospital, UK Who are you & what is your relationship to OI? I am a physician and rheumatologist with a special interest in the treatment of bone diseases. I have been taking care of patients…
